



Antimicrobial Resistance and Infection Control

Guest Editor:

Dr. Dino Sgarabotto

Policlinico di Abano, Piazza
Cristoforo Colombo 1, 35031
Abano (PD), Italy

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance (AMR) is recognized by the World Health Organization as a priority, one of the top ten global public health threats facing humanity—even in the face of the worldwide challenge of the COVID-19 pandemic. Although AMR is a problem, it is not an unmanageable problem; indeed, between 2014 and 2017, the use of antibiotics in people dropped down by 7.3% at least in the UK. According to the WHO, the overuse of medicines in humans, livestock, and agriculture, as well as poor access to clean water, sanitation, and hygiene are some of the factors that have accelerated the AMR threat worldwide. Without effective antibiotics, the success of modern medicine in treating infections, including antimicrobial therapy during major surgery and cancer chemotherapy, would be at increased risk.

The aim of this Special Issue is to gather new information of the spread of AMR in the community as well as in the hospital settings, but also to collect specific clinical experiences with new antibiotics against MDR microorganisms.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi